The USA's Centers for Medicare and Medicaid Services (CMS) has been criticized for its "near-total failure," according to Senate Finance Committee Chairman, Max Baucus (Democrat, Montana), to provide appropriate sample documents to health care insurers in the run up to the launch of the Medicare Part D prescription drug benefit in 2006 (Marketletters passim).
Although a CMS spokesman told the Associated Press that most of the problems have been resolved, following an Office of the Inspector General report, it also emerged that many marketing materials were not reviewed by the CMS within 18 months.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze